Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17920045 | 1.00 | GRIK1 (0.37) | GRIK1GRIK2ECE1ALDH1A1MAPT | |
| SCHEMBL15909791 | 1.00 | GRIK1 (0.37) | GRIK1GRIK2ECE1ALDH1A1MAPT | |
| SCHEMBL13540707 | 1.00 | GRIK1 (0.37) | GRIK1GRIK2ECE1ALDH1A1MAPT | |
| SCHEMBL14852861 | 1.00 | GRIK1 (0.37) | GRIK1GRIK2ECE1ALDH1A1MAPT | |
| SCHEMBL19984497 | 0.84 | GRIK1 (0.39) | GRIK1GRIK2ECE1 | |
| SCHEMBL13447538 | 0.84 | GRIK1 (0.39) | GRIK1GRIK2ECE1 | |
| SCHEMBL3966053 | 0.82 | GRIK1 (0.38) | GRIK1GRIK2MAPT | |
| SCHEMBL3966055 | 0.82 | GRIK1 (0.38) | GRIK1GRIK2MAPT | |
| SCHEMBL17524625 | 0.81 | GABRR1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL17087511 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | GLAS USA LLC | 2023-02-09 | — | — | US | disclosed |
| US-10738084-B2 | Macrocycles | SENTRY THERAPEUTICS LIMITED (GB) | 2020-08-11 | — | — | US | disclosed |
| US-20200171122-A1 | CYCLOSPORIN ANALOGUES AND USES THEREOF | DYNEQ MEDICAL LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10471058-B2 | Pharmaceutical formulations and their use in the treatment of periodontal disease | PERIOC LTD (GB) | 2019-11-12 | — | — | US | disclosed |
| US-20180186836-A1 | NOVEL MACROCYCLES | Cypra;os Limited (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180153958-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. | 2018-04-05 | — | — | US | disclosed |
| US-9914755-B2 | Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized | ALLERGAN, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9895412-B2 | Cyclic depsipeptide compounds and their uses | CYPRALIS LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| EP-2855508-B1 | CYCLOSPORIN A ANALOGS | ALLERGAN INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-7696165-B2 | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696166-B2 | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100009953-A1 | CYCLOSPORIN DERIVATIVES FOR TREATING OCULAR AND DERMAL DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7632807-B2 | Cyclosporin alkynes and their utility as pharmaceutical agents | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7538084-B2 | Cyclosporins | AMR TECHNOLOGY, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7511013-B2 | Cyclosporin analogues and their pharmaceutical uses | AMR TECHNOLOGY, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080249002-A1 | CYCLOSPORIN ALKYNE ANALOGUES AND THEIR PHARMACEUTICAL USES | AMR TECHNOLOGY, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080153744-A1 | NOVEL CYCLOSPORIN ALKYNES AND THEIR UTILITY AS PHARMACEUTICAL AGENTS | AMR TECHNOLOGY, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7361636-B2 | Cyclosporin alkynes and their utility as pharmaceutical agents | AMR TECHNOLOGY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7196161-B2 | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection | SCYNEXIS INC. (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009953-A1 | CYCLOSPORIN DERIVATIVES FOR TREATING OCULAR AND DERMAL DISEASES AND CONDITIONS | HRH4, HCAR3, NR1H4 | GRIK1 3311/4885GRIK2 3289/4885ECE1 406/4885 |
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | CHP1, PPIB, FKBP1B | GRIK1 3920/4885GRIK2 3954/4885ECE1 1824/4885 |
| US-20080153744-A1 | NOVEL CYCLOSPORIN ALKYNES AND THEIR UTILITY AS PHARMACEUTICAL AGENTS | CHP1, PPP3R1, CX3CR1 | GRIK1 4170/4885GRIK2 4708/4885ECE1 1228/4885 |
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | FABP2, IL2, TSLP | GRIK1 4048/4885GRIK2 3140/4885ECE1 4102/4885 |
| US-20180153958-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | GRIK1 4431/4885GRIK2 4506/4885ECE1 487/4885 |
| US-20200171122-A1 | CYCLOSPORIN ANALOGUES AND USES THEREOF | CHP1, C1S, C5 | GRIK1 4214/4885GRIK2 4487/4885ECE1 1326/4885 |
| US-10738084-B2 | Macrocycles | MC2R, C1R, CCNI | GRIK1 3482/4885GRIK2 3834/4885ECE1 809/4885 |
| US-20080249002-A1 | CYCLOSPORIN ALKYNE ANALOGUES AND THEIR PHARMACEUTICAL USES | PPP3R1, CCR7, CHP1 | GRIK1 4237/4885GRIK2 4555/4885ECE1 1062/4885 |
| US-10471058-B2 | Pharmaceutical formulations and their use in the treatment of periodontal disease | PPIG, PPIH, PPIL1 | GRIK1 4041/4885GRIK2 3860/4885ECE1 1035/4885 |
| US-20180186836-A1 | NOVEL MACROCYCLES | MC2R, CCNI, CCNE1 | GRIK1 3210/4885GRIK2 3643/4885ECE1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.